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Chemical Synthesis of Phosphatidylinositol Mannoside Glycans from 
Mycobacterium tuberculosis 
Field of the invention 
The invention relates to phosphatidylinositol mannoside (PIM) glycans carrying a reactive 
functional group, a carrier protein, a fluorescent probe, an antigen or a solid phase, and to 
a vaccine containing such PIMs carrying an antigen. 
10 Background of the invention 
Tuberculosis (TB) is a complex disease and a major cause of mortality world-wide. 
Despite the development of new treatments, TB remains a global health concern. 
Annually, there are more than seven million new cases and two million deaths caused by 
15 TB (C. Martin, Eur Respir J 2005, 26:162-167). Coinfection with HIV leads to an 
exacerbation of the disease and contributes to higher mortality in HIV patients. Programs 
to combat TB in many countries have failed to eradicate TB, partly due to the spread of 
multidrug-resistant TB and the low efficacy of the BCG vaccine. Therefore, the exploration 
of novel drug targets and vaccines against Mycobacterium tuberculosis (Mtb), the main 
20 causative pathogen of TB, is essential. 
Among pathogenic bacteria, Mtb causes more deaths in humans than any other 
pathogen. Approximately one third of the world population has already been infected by 
Mtb. Mtb is an intracellular pathogen that has evolved to persist efficiently in infected 
25 macrophages. The composition of the Mtb cell wall is important for the interaction with 
host cells during the initial steps of the infection. Later, cell wall components play a crucial 
role in modulating the pro-inflammatory response by macrophages and also serve as a 
protective barrier to prevent anti-tuberculosis agents from permeating inside. 
Consequently, the antibiotics used for the treatment of tuberculosis require long term 
30 administration (J.C. Sacchettini, E.J. Rubin and J.S. Freundlich, Nat Rev Microbial 2008, 
6:41-52). Mortality in people living in developing countries is high since their access to 
these antibiotics is often limited and compliance with treatment courses is low. 
The major components of the mycobacterial cell wall are the mycoyl arabinogalactan-
35 peptidoglycan (mAGP) complex and interspersed glycolipids including ManLAM, LAM, 
LM, and PI Ms. While the mAGP complex is covalently attached to the bacterial plasma 
CONFIRMATION COPY 
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membrane, the glycolipids are non-covalently attached through their phosphatidyl-myo-
inositol (PI) anchor. PIMs constitute the only conserved substructure of LM, LAM and 
Man LAM (Figure 1 ). The inositol residue of PI is mannosylated at the C-2 position to form 
PIM1 and further at the C-6 position to form PIM2 , one of the two most abundant naturally 
5 occurring PIMs, along with PIM6 . Further a-1 ,6 mannosylations give rise to PIM3 and PIM4, 
the common biosynthetic precursors for PIMs, PIMs and the much larger LM structures. 
LAM is constituted by attachment of arabinans- the repeating units of a-1 ,5 arabinose 
terminated with a single [3-1 ,2 arabinose- to unknown mannose units of LM. The non-
reducing end arabinose in the arabi nan moiety of LAM can be capped at the C-5 position 
10 with one or two a-mannose units to furnish Man LAM. 
Among the surface components involved in the Mtb interaction with host cells, PIMs play a 
crucial role in the modulation of the host immune response. The functional importance of 
PIMs was emphasized by the finding that PIMs bind to receptors on both phagocytic (J.B. 
15 Torrelles et al., J. lmmunol 2006, 177:1805-1816) and nonphagocytic (H.C. Hoppe et al., 
Infect lmmun 1997, 65:3896-3905) mammalian cells. Recently, it has been shown that 
PIMs, but neither LAM nor ManLAM interact with the VLA-5 on CD4+T lymphocytes and 
induce the activation of this integrin (R. E. Rojas et al., J lmmunol 2006, 177:2959-2968). 
These·findings suggest that PIMs are not only secreted to the extracellular environment, 
20 but also exposed on the surface of Mtb to interact with host cells. 
Although different functions have been ascribed to the PIMs, it remains to be determined 
whether and to which extent the different PIM substructures display biological activity. A 
better understanding of the mycobacterial cell wall biosynthesis is required to be able to 
25 counteract with the problems of drug resistance and bacterial persistence. Synthetic PIMs 
represent important biochemical tools to elucidate biosynthetic pathways and to reveal 
interactions with receptors on host cells. PIMs are potential vaccine antigens and/or 
adjuvants. 
30 Several synthetic PIMs containing fewer mannoside units have been synthesized 
employing various chemical methodologies. In contrast to PIM3 and PIM4 that contain only 
a-1 ,6 mannosidic linkages, PIM5 and PIM6 also incorporate a-1 ,2 mannosides that might 
contribute to different biological activities of these PI Ms. None of the studies to date 
utilized synthetic PIMs that contain linkers for immobilization. Coupling of synthetic PIMs 
35 to carrier proteins, beads, quantum dots, microarray or surface plasmon resonance (SPR) 
surfaces opens a host of options for biochemical studies. 
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Summary of the invention 
The invention relates to a compound of formula (I) 
(I) 
5 wherein 
RA isH, a mannoside, di-mannoside, tri-mannoside, tetra-mannoside or penta-mannoside 
of formula (II), (Ill), (IV), (V) or (VI) below, respectively; and 
R8 is -(CH2)n-X wherein n is between 2 and 10 or -(CH2CH20)mCH2CH2X wherein m is 
between 1 and 5, and X is a reactive functional group, a carrier protein, a fluorescent 
10 probe, an antigen or a solid phase. 
The invention further relates to vaccines comprising a compound of formula (I) wherein X 
is a carrier protein or an antigen. 
15 Brief description of the Figures 
Figure 1. Structural features of PIMs, LM, LAM and ManLAM of Mycobacterium 
tuberculosis. PIMs are the common precursors of more complex components of the 
mycobacterial cell wall including lipomannan (LM), lipo-arabinomannan (LAM), and 
20 mannan capped lipo-arabinomannan (Man LAM). (a, b, and care varied; typically, R2 is 
tuberculostearic acid, R1 and R3 are various fatty acids.) 
Figure 2: 
1: KLH alone 
25 2: KLH + Freund's adjuvant 
3: KLH +Alum 
4: KLH + CpG 
5: KLH-PIMs (covalent) 
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The experimental procedure is described below under the title "Immunization of mice and 
detection of anti-KLH antibody levels in sera". 
Figure 3A. B: 
5 Immunization was performed as described below under the title "Immunization of mice 
and detection of anti-KLH antibody levels in sera". Levels of anti-KLH antibody subclasses 
(anti-KLH lgG1 and lgG2a) in sera of immunized mice were measured by ELISA. 
Meaning of 1, 2, 3, 4, 5, 6 see Fig. 2. 
10 Figure 4: 
Mice were immunized as described below under the title "Immunization of mice and 
detection of anti-KLH antibody levels in sera". On day 20, spleens were removed and 
splenocytes were isolated as described below under the title "T cell proliferation and 
ELISpot analysis". The results are expressed as a stimulation index (SI) which is the net 
15 proliferation of lymphocyte cultures stimulated with KLH divided by the net proliferation of 
lymphocyte cultures in medium. 
Meaning of 1, 2, 3, 4, 5, 6 see Fig. 2. 
Figure 5: 
20 Mice were immunized as described below under the title "Immunization of mice and 
detection of anti-KLH antibody levels in sera". On day 20, spleens were removed and 
splenocytes were isolated as described below under the title "T cell proliferation and 
ELlS pot analysis". The results are expressed as spot forming units (sfu) which is the 
number of IFN-y producing cells per total cells (2x1 05). Dashed lines represent number of 
25 IFN-y spots measured when splenocytes from unimmunized mice were stimulated with 
ConA or KLH. 
Meaning of 1, 2, 3, 4, 5, 6 see Fig. 2. 
30 Detailed description of the invention 
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and R8 is -(CH2)n-X wherein n is between 2 and 10 or -(CH2CH20)mCH2CH2X wherein m 
is between 1 and 5, and X is a reactive functional group, a protein, a fluorescent probe or 
a solid phase. 
5 The compound of formula (I) wherein RA isH is called PIM 1• The compound of formula (I) 
wherein RA is a residue of formula (II) is called PIM2. The compound of formula (I) wherein 
RA is a residue of formula (Ill) is called PIM3. The compound offormula (I) wherein RA is a 
residue of formula (IV) is called PIM4 . The compound of formula (I) wherein RA is a 
residue of formula (V) is called PIM5 . The compound of formula (I) wherein RA is a residue 
10 of formula (VI) is called PI Ms. 
The native diacylglycerol phosphate at the C-1 position of myo-inositol is replaced by the 
residue R8 connected .to the phosphate residue. 
15 In R8 with the meaning -(CH2)n-X, n is between 2 and 10, preferably between 3 and 8, for 
example 3, 4, 5, 6 or 7, preferably 4, 5 or 6, most preferably 6. 
20 
In R8 with the meaning -(CH2CH20)mCH2CH2X, m is between 1 and 5, preferably 1, 2 or 
3, in particular 2. 
X as a reactive functional group is a functional group suitable for coupling the PIM 
compound to a protein (including a proteinaceous antigen), to a fluorescent probe or to a 
solid phase. A preferred example of a reactive functional group is the sulfhydryl group 
(-SH), which can be reacted with a protein, a fluorescent probe or a solid phase carrying 
25 a maleimido function, which then leads to a thiosuccinimido group. Another preferred 




which can be reacted with a protein, a fluorescent probe or a solid phase carrying a 
sulfhydryl function again resulting in a thiosuccinimido group. A further suitable reactive 
30 function is an amino group, which can be reacted with a protein, a fluorescent probe or a 
solid phase carrying an optionally activated carboxyl group. The carboxyl may be 
activated by any of the standard activating reagent used for amide bond formation as is 
widely known in peptide chemistry, for example as a 1-hydroxybenztriazole or N-
wo 2010/051961 PCT/EP2009/007845 
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hydroxysuccinimide ester. The corresponding optionally activated carboxy group is 
another suitable reactive functional group X, which then may react with an amine function 
in a protein, a fluorescent probe or a solid phase. 
5 X as a protein is preferably a carrier protein useful in a vaccine. Examples of carrier 
proteins are bovine serum albumin (BSA), ovalbumin (OVA), keyhole limpet hemocyanin 
(KLH), thyroglobulin, and tetanus toxoid. Preferred carrier proteins are KLH and OVA. X 
with the meaning protein may further comprise functional groups linking the protein to the 
alkylene group or polyethyleneoxy group defined in R6 , preferably a thiosuccinimido group 
10 obtained on reaction of a sulfhydryl function -SH with a maleimido function of formula 
(VII), or an amide function obtained on reaction of an amine with an activated carboxyl 
function. 
An antigen X may be any useful antigen considered to be used in a vaccine. Usually this 
15 antigen is not antigenic enough to give rise to an immunogenic response of a host when 
injected into the host, but may elicit such a reaction after conjugation to a PIM as defined 
under formula (1). Examples of antigens considered are keyhole limpet hemocyanin (KLH), 
HBs antigen (from hepatitis 8 virus, HBV), pertussis, diphtheria and tetanus toxoid 
antigen, and surface antigens of pathogens with low immunogenicity, such as malaria, 
20 schistosomiasis, or HIV. In principle all proteins from bacteria, viruses, parasites or fungi 
can be considered as suitable antigens. As is described above for X as a carrier protein, X 
with the meaning antigen may further comprise functional groups linking the antigen to the 
alkylene group or polyethyleneoxy group defined in R6 . 
25 A fluorescent probe X considered for conjugation to PIMs is, for example, fluorescein, 
Texas red, Tokyo green, Pennsylvania green, rhodamines, Cy5, Cy3, green fluorescent 
protein, BFP, mTFP1, emerald, citrine, mOrange, mApple, mCherry, mGrape and other 
fluorophores, and also fluorescent nanocrystals. A fluorescent probe X may further 
comprise functional groups linking the antigen to the alkylene group or polyethyleneoxy 
30 group defined in R6 , for example a thiosuccinimido function or an amido function as 
explained above. 
A solid phase X may be a standard solid material used for sugars and proteins, e.g. a 
glass slide, plastic slide or beads made of silica, alex or other suitable carrier materials 
35 further comprising a suitable functional group connecting the solid phase to the alkylene 
wo 2010/051961 PCT/EP2009/007845 
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group or polyethyleneoxy group defined in R8 , for example a thiosuccinimido function or 
an amide function as explained above. 
Preferred are compounds of formula (I) wherein, RA is a residue of formula (I), (II), (Ill), 
5 (IV), (V) or (VI), R8 is -(CH2)n-X wherein n is between 2 and 10, and X is a reactive 
functional group. Most preferred are the compounds of the following formula designated 
PIM1, PIM2, PIM3, PIM4, PIM5 and PIMa, wherein R8 is -(CH2)a-SH, in particular the 
compounds PIM2 and PIMa. 
10 
H~OH HO .o 
HO 0 OH fi0'6H H~l, HO .o 
HO~ HO 
0 OH H0~0 HO 0 
OH 
· 0 OH 




HO OH PIMs H~[-, 
HO~ 
H~j.\ HO:::>~ 
HO H':0.3~, HO~O~~ 
HO~ HO 




H~OH HO .o 
HO 
PIM6 
H~O HO .o 
HO 
HO .o H~O
HO o OH ~O~H HO~l, HO -0 HO~ HO 
0 OH H~T,_ 
HO~ 0 OH A-r-L/~OH 
O O~OH ~rJ.. ~SH 
- I 0 
0 
PCT/EP2009/007845 
5 The invention further relates to vaccines comprising a compound of formula (I) wherein X 
is a carrier protein or an antigen. Preferred vaccines wherein the PIMs act as adjuvants 
are conjugates with antigens selected from HBs, pertussis, diphtheria, tetanus toxoid, 
malaria, schistosomiasis, and HIV antigens. In principle all vaccines consisting of protein 
antigens from bacteria, viruses, parasites or fungi can be considered as suitable. 
10 
Retrosynthetic analysis. The overall structure of the synthetic PIM targets of f<:>rmula (I) 
can be attained by the convergent union of oligomannosides with o-myo-inositol 
containing pseudosaccharides and a residue R9 , e.g. the thiol-terminated phosphate linker 
wo 2010/051961 PCT/EP2009/007845 
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(Scheme 1). Late-stage couplings between protected oligosaccharide fragments (1-4) and 
8 allow for parallel syntheses of the intermediates for all target molecules. The key 
glycosylations in these syntheses are the couplings between mannosyl phosphate 1, 
oligomannosyl trichloroacetimidates (2-4) and the common pseudotrisaccharide 8. The 
5 two main carbohydrate moieties are coupled, followed by protecting group manipulations. 
10 
Subsequently, a phosphate diester linker is installed using an H-phosphonate followed by 
oxidation of phosphorus. Since the preferred target molecules contain sulfur in the residue 
R8 that is known to deactivate the Pd/C catalyst, the permanent benzyl protecting groups 
are globally removed via Birch reduction. 
The stereoselectivity of each glycosydic bond formation is ensured by neighboring C-2 
acyl participating groups. Anomeric dibutyl phosphate ester was employed as a leaving 
group for the man nose building blocks that can be readily prepared. This method proved 
advantageous when compared to previous PIM syntheses. Three mannose building 
15 blocks (1, 5, and 1 0) are needed in addition to the inositol building block. 
Scheme 1. Retrosynthetic analysis for the assembly of synthetic PIMs 
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Syntheses of Monosaccharide Building Blocks. Mannosyl building blocks 1, 5, and 10 
were synthesized from mannose bicyclic and tricyclic orthoesters (6, 12) (A. Ravida et al., 
Org Letters 2006, 8:1815-1818). Starting from o-mannose, mannosyl phosphate 1 was 
accessed in six steps by dibutyl phosphoric acid opening of the bicyclic orthoester 7. 
5 Mannosyl tricyclic orthoester 6 is readily available from o-man nose over six high yielding 
steps. This process required only one purification at the last step and gave 6 in 70% 
overall yield. The versatile intermediate 6 was opened by allyl alcohol upon activation with 
BF3·Et20 to afford 5 in excellent yield. Treatment of orthoester 6 with dibutyl phosphate 
selectively opened the tricyclic orthoester to furnish glycosyl phosphate 13, leaving the C-
1 0 6 hydroxyl group unprotected. The installation of a triisopropylsilyl (TIPS) group was 
straightforward and furnished building block 10. 
15 
Scheme 3. Efficient multi-gram preparations of mannose building blocks via bicyclic and 
tricyclic orthoester intermediates 
HO~ Me Me HO 0 a AcO XOMe Bn~OMec ~ b 1 HO AcO O BnO -O O 
HO A cO BnO 
o-Man nose 7 12 
dl 
H~ Ph BnO .o fJl e BnO 0 f II 0-P-OBu 10 9 13 bBu 
BnO OBn 5 
6 
Reagents and conditions: (a) i. Ac20, HCI04 (cat.), ii. HBr I HOAc, iii. MeOH, Lutidine, 
90%, three steps; (b) i. NaOMe I MeOH I THF, ii. NaH, BnBr, DMF, quant. two steps; 
(c) HOP(O)(OBu)2, 4A MS 93%; (d) i. BzCI, Py, ii. HBr I HOAc, iii. AIIOH, Lutidine, 
20 iv. NaOMe I MeOH I THF, reflux, v. CSA, MeCN, vi. NaH, BnBr, DMF, 70%, six steps; 
(e) HOP(O)(OBu}2, 4A MS, 97%; (f) TIPSCI, NEh, DMAP, CH2CI2 , 91 %; (g) AIIOH, 
BF3-Et20, CH2CI2 , 99%. 
The previously reported synthetic route to the differentially protected myo-inositol by 
25 Fraser-Reid et al., J Chern Soc, Perkin Trans I 1998:631 was modified (Scheme 4). 
Methyl glucopyranose was quantitatively converted to 15 in three consecutive steps. A 
Parikh-Doering reaction oxidized the primary hydroxyl group in 15 to an aldehyde in 
quantitative yield. Using this oxidation, complications arising from the urea byproduct 
created when dicyclohexylcarbodiimide (DCC) was used as activator were avoided. The 
30 sulfate byproduct was readily removed by water extraction. The partially protected myo-
wo 2010/051961 PCT/EP2009/007845 
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inositol16 was prepared from compound 15 in 40% yield over four consecutive steps. The 
allyl and NAP protecting groups were introduced at C1 and C2 of the o-myo-inositol 
respectively to furnish 11, ready for further decoration at the C6 hydroxyl group. 
5 Scheme 4. Synthesis of 1-0-acetyl-3,4,5-tri-0-benzyl-myo-inositol (16) 
H~~q a )~ 
OMe 
14 




HO_J>H /~OBn_C ___ 11 AcO~OBn 
16 
Reagents and conditions: (a) i. Imidazole, TIPSCI, DMF ooc tort, ii. NaH, BnBr, DMF, ooc 
tort, iii. TBAF, THF, 99%, three steps; (b) i. S03-Py, DIPEA, DMSO, CH2CI2, ooc tort, 
10 ii. K2C03, Ac20, MeCN, reflux, iii. Hg(CF3C00}2, Acetone I H20 (4:1), rt, 1 h, then NaOAc 
(aq), NaCI (aq), ooc to rt, iv. NaBH(CH3COOh, AcOH, MeCN, ooc to rt, 40%, four steps. 
(c) (i) CH2CHOEt, PPTS, then NaOMe, MeOH, (ii) AIIBr, NaH, then 2N HCI, 84%, two 
steps, (Ill) NAPBr, NaH, TBAI,DMF, 81 %; 
15 Assembly of myo-inositol containing pseudosaccharides. The myo-inositol containing 
pseudotrisaccharide 8 was assembled in a stepwise manner. Glycosylation of inositol 11 
with mannosyl phosphate 10 that contained a C6-TIPS ether as temporary protecting 
group was found to be optimal at -40°C, in toluene, and promoted by a stoichiometric 
amount of TMSOTf (Scheme 5). Under these conditions the reaction gave a good yield 
20 with complete a-selectivity. To sustain further glycosylations, the temporary TIPS 
protecting group was replaced by the levulinoyl (Lev) group. The presence of TIPS rather 
than Lev on the C6 hydroxyl group of 10 was found necessary to balance its reactivity with 
inositol10 to obtain high yield and selectivity. Treatment of 19 with DDQ unmasked the 
C2 hydroxyl group on inositol to give 20 that served in turn as nucleophile during the next 
25 mannosylation. 
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Scheme 5. Assembly of myo-inositol containing pseudotrisaccharide 8 
a ,~;~~~~n 0 OBn d 10 + 11 ----• AIIO OBn ------
Lev~O OBz 





bC17: R~: TIPS 
0 c~18. R - H BnO OAc 
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BnO 
R20 OBz Bn~0~ 
e BnO~ 0 OBn 
------ O~OBn (Table 1) AIIO~OBn 
f 21: R2 =Lev C 8: R2 = H 
Reagents and conditions: (a) TMSOTf, Toluene, -40°C, 90%; (b) AcCI, MeOH, CH2CI2, 
5 0°C, quant.; (c) LevOH, DIPC, DMAP, quant.; (d) DDQ, CH2CI2 , MeOH, 0°C, 95%; 
10 
(e) 1, TBDMSOTf, Toluene, -40°C, 95%, (see Table 1 ); (f) H2NNH30Ac, MeOH, rt, 89%. 
Table 1. Effects of promoter and temperature on the glycosylation of glycosyl phosphate 1 
and myo-inositol intermediate 20 
Entry Promoter Temperature ( °C) Yield(%) 
1 TMSOTf -40 15 
2 TBDMSOTf -40 27 
3 TBDMSOTf -10 57 
4 TBDMSOTf 0 55 
5 TBDMSOTf rt 95 
The second mannosylation on the C2 hydroxyl group of pseudodisaccharide 20 was found 
to be nontrivial (Table 1 ). Activation by TMSOTf afforded the desired pseudodisaccharide 
21 in just 15% yield (Table 1, Entry 1 ). Decomposition of 1 to form the anomeric alcohol 
15 was observed instead. Switching the promoter from TMSOTf to the milder activator 
TBDMSOTf dramatically improved the yield of the desired product (Table 1, Entry 2). This 
observation suggested a possible reactivity mismatch between highly activated 1 and less 
activated 20. The glycosylation was thus improved by reducing the reactivity of 1 with 
TBDMSOTf. Product 21 was obtained in excellent yield (95%) and selectivity by 
20 performing the glycosylation at ooc (Table 1, Entry 5). The a linkages in 21 were 
confirmed by 20 NMR. 1H- 13C coupled HSQC NMR indicated 1H1- 13C1 coupling 
constants (Jc1,H1) of 178 Hz at the anomeric position of the mannose connected to the C2 
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of inositol and 182 Hz at the anomeric position of the man nose on C6 of inositol. Jc1,H1 of 13 
mannosidic linkages are typically lower at around 159 Hz (C.A. Pod Iasek et al., J Am 
Chern Soc 2006, 128:33638-3648). 
5 Removal of the Lev group in 21 was achieved by treatment with hydrazine acetate in 
methanol and required careful monitoring. Longer reaction times resulted predominantly in 
the reduction of the allyl moiety to a propyl group. Partially protected inositol 16 was 
subjected to protecting group manipulations to furnish the inositol intermediates for PI and 
PIM1 (Scheme 6). Based on reactivity differences, the equatorial C6 hydroxyl group of the 
10 dial 22 was selectively acetylated to afford 23 as the intermediate en route to PIM1. The PI 
intermediate 24 was obtained in parallel by benzylation of the common intermediate 22. 
15 
20 
Scheme 6. Protecting group manipulations on myo-inositol 16 for PI intermediate 23 and 
PIM1 intermediate 24 
OH 
OB 
b AcO OBn 
~AIIO OBn 
OH ~ 23 
HO_...j p~OBn 
16 ----- AIIO~OBn OBn 
22 ~ C BnO __..j p~OBn ~AIIO~OBn 
a 
24 
Reagents and conditions: (a) (i) CH2CH0Et, PPTS, then NaOMe, MeOH, (ii) AIIBr, NaH, 
then 2N HCI, 84%, two steps; (b) Ac20, DMAP, Py, 70%; (c) NaH, BnBr, DMF, ooc tort, 
quant. · 
Assembly of o/igomannoside fragments. The oligomannoside trichloroacetimidates 2, 3, 
and 4 were assembled in linear fashion (Scheme 7). All glycosylations employed 
mannosyl phosphate 1 and TMSOTf as activator. The a-1 ,6 glycosydic bond was readily 
formed at ooc in quantitative yield. A lower temperature (-40°C} was required to efficiently 
25 install 1 ,2 glycosylic linkages with complete a-selectivity. Deallylation of 25-27 was 
performed by allylic substitutions mediated by a palladium complex to yield the 
corresponding anomeric alcohols 28-30. Finally, conversion to the glycosyl 
trichloroacetimidates 2- 4 were carried out using sodium hydride as base. 
Scheme 7. Assembly of oligomannosylating reagents 2-4 for the synthesis of PIM2-PIM6 
1 + 5 a 
B~O 0~1 BnO . 
BnO 
• ~0 OBz BnO · Bn 
OR2 
25: R1 = Acl R2 = All 
fj 
bl c 
28: R1 = Ac I R2 = H 
9










26: R3 = Acl R4 =All 
f j 
die 
29: R3 = Ac I R4 = H 
9










~08z 8n0 Bn 
OR6 
27: R5 =Acl R6 =AII 
fj 
30: R5 = Ac I R6 = H 
9
[ 4: R5 = Ac , R6 = C(NH)CCI3 
5 Reagents and conditions: (a) TMS0Tf1 CH2CI21 -1 0°C1 quant.; (b) AcCI, Me0H1 CH2CI2, ooc, 91 %; (c) 1, TMSOTf, -40°C, Toluene, 95%: 
(d) AcCI, MeOH, CH2CI2, 0°C, 84%; (e) 1, TMSOTf, Toluene, -40°C, 96%; (f) Pd(OAc)2, MeOH, PPh3, Et2NH, 77% for 28, 95% for 29, and 
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Assembly of protected PIM backbones. Prior to phosphorylation, all protected PIM 
oligosaccharide backbones were obtained by late-state glycosylations (Table 2). Following 
these glycosylations all ester protecting groups were removed with sodium methoxide in 
methanol at elevated temperature before masking the free hydroxyl groups as benzyl 
5 ethers. These protecting group manipulations were performed to avoid the persistence of 
0-benzoate protecting groups under Birch conditions in the final deprotection. 
10 
Table 2. Assembly of fully protected PIM1-PIM6 backbones: Union of (oligo)mannosyl 
fragment (X) and inositiol-containing pseudosaccharide fragment (Y) 
/ 
X+Y 
a) Glycosylation (except entry 2) 
b) NaOMe/ MeOH, 50 °C, 24 h 
c) BnBr, NaH, 0 octo rt, 12 h Differentially Protected 
PIM2 - PIM6 
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(Table 2 continued) 
Entry X y Glycosylation Products 
conditions 




·~ BnO O BnO ·~ BnO O BnO ~ 
0 OBn 
AIIO OBn 




3 1 8 TMSOTf, Bn~ BnO O 
-10°C, CHzCiz 33: R1 = BnO 
4 2 8 TMSOTf, B~ 
-10°C, CHzCiz BnO O BnO 
0~ BnO O 
34: R1= 
BnO 
5 3 8 TMSOTf, B~ BnO O 
-1 0°C, CHzCiz BnO 
B~ BnO O 
BnO 
~ BnO O 35:R1= BnO 
6 4 8 TMSOTf, B~ BnO O 
0°C, CHzCiz 
36 R1 :~0:~~). 
· BnO 
B~~ 
36: R1 = Bn 
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Coupling between mannosyl phosphate 1 and inositol 23 gave pseudodisaccharide 31, 
the backbone of PIM1. To access the PIM2 backbone, pseudotrisaccharide fragment 8 
was directly used as the starting material to be transformed into backbone 32. The 
glycosylation products from couplings (Table 2, entry 3-5) between the oligomannosyl 
5 trichloroacetimidates (1-3) and the common pseudotrisaccharide 8 were cleanly achieved 
at -1 0°C. After quenching with triethylamine, the concentrated crude products were 
directly converted to obtain the benzylated products. When the larger structure 4 was 
used for glycosylation, the coupling became more sluggish and resulted in the hydrolysis 
of 4. A higher temperature (0°C} was needed to obtain the 4 + 3 glycosylation product 46 
10 (see experimental section). Pseudoheptasaccharide 46 was the largest oligosaccharide 
assembled in this series and consisted of fragments of all smaller oligosaccharides. Thus, 
46 was analyzed extensively by C-H coupled HSQC to confirm its structural identity. 20-
NMR data elucidated six anomeric proton signals with typical a-manno Jc1,H1 couplings. 
15 Removal of 0-a//y/ protecting group on inositol. Protocols to cleave the C-1 0-allyl group 
on inositol attached to oligosaccharides, performed by using PdCb. usually give moderate 
yields. Different methods to remove the 0-allyl group were explored on substrate 31 
(Scheme 8 and Table 3). The hydrogen activated iridium complex lr {(COD)[PH3(CsHshM 
PF6 was found to be the most efficient reagent to isomerize the allyl group to the 
20 corresponding enol ether. In the same pot, a catalytic amount of p-toluenesulfonic acid 
(p-TsOH) was added to cleave the enol ether and liberate the C1 hydroxyl of pseudo-
disaccharide 38 in quantitative yield. This two step procedure was applied to the larger 
oligosaccharides 32 to 36 as well. However, while the isomerizations mediated by the 
iridium complex worked smoothly, an excess of p-TsOH (10 equiv.) was required to 
25 cleave the enol ether and furnish 39 - 43 (Scheme 8, entry 3). 
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1BuOK, DMSO, 80 °C, 
then 12, THF I H20 (4:1) 
80% 
Deallylations (Table 3) 
5 Table 3. Removal of allyl protecting group on pseudo-disaccharide 31 
Entry Conditions Yield 
1 18uOK, DMSO, 80°C, then 12. THF I H20 TMSOTf 10%, 
(decomposition) 
2 Pd(OAc)2, PPh3, HNEh, CH2CI2 I MeOH (2: 1) no reaction 
3 [lr(COD)(PCH3Ph2h]PF6 (cat.), H2, THF then 12 in THF I H20 30% 
(2:1) 
4 [lr(COD)(PCH3Ph2h]PFs (cat.), H2, THF then p-TsOH (cat.) in quantitative 




R1~0 OBn b) p-TsOH (1 0 eq.), rt, MeOH, CH2CI2 BnO~:· 
BnO~ 0 OBn BnO 0 OBn n~OBn AIIO~sn R1 shown in Table 2 
32 - 36 
O~OBn HO~OBn 
39 (71%), 40 (81%), 41 (79%), 
42 (87%), 43 (89%), respectively 
10 Phosphorylation and global deprotection. The phosphate moiety accompanied with a 
terminal thiollinker was installed on the inositol C1 hydroxyl group of the oligosaccharide 
backbone 37 - 43 using a H-phosphonate (Scheme 9). Substrates 37 - 43 were treated 
with pivaloyl chloride in the presence of linker 44 and pyridine. Subsequently, in the same 
pot, the H-phosphonate diesters were oxidized with iodine and water to provide the fully 
15 benzylated phosphodiesters 45 as triethylamine salts in excellent yield. Global removal of 
benzyl protecting groups of analogs 45(a-g) was achieved under Birch reduction 
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conditions. The fully protected compounds were treated with sodium dissolved in 
ammonia to furnish the final products PI and PIM1 - PIM6 with a sulfhydrylhexyl residue R2. 
Small amounts of incompletely reduced products were observed containing some 
remaining benzyl groups. These side products were separated by extraction with 
5 chloroform and converted to the final products by re-submission to Birch reduction. The 
final products were formed as a mixture of monomers and disulfide dimers. Treatment 
with one equivalent of tris(carboxyethyl} phosphine hydrochloride (TCEP) immediately 
prior to conjugation of the final compounds ensured that PI and PIM1 - PIMs with a 
sulfhydrylhexyl residue R2 were present as monomers. 
10 
The procedure may easily adapted in using a linker 44 with different length of alkyl chain 
and/or with a different protected functional group, e.g. carrying a maleimido functional 
group, a protected amino function or a protected carboxylic acid function. 
15 Scheme 9. Phosphorylation of oligosaccharides 37-43 and global deprotection under 
Birch reduction conditions 
20 Reagents and conditions: (a) i. 44, PivCI, pyridine, ii. 12, H20, pyridine, 90% to quant., 
2 steps; b) i. Na I NH3 (I) I t-BuOH, -78°C, ii. MeOH, 65% for PI, 43% for PIM1, 56% for 
PIM2, 91% for PIM3, 65% for PIM4 , 88% for PIM5, and 84% for PIM6. 
PI M microarrays to determine binding to DC-SIGN. To study the interactions of synthetic 
25 PI and PIMs with the protein DC-SIGN on a microarray, PI and PIMs were immobilized on 
a maleimide activated glass slide via their thiol handle following established protocols. 
DC-SIGN is an important receptor on dendritic cells and contributes to the initiation of a 
pro-inflammatory response by host cells. One of the functions of DC-SIGN is the 
recognition of evolutionary conserved pathogenic structures that are secreted or exposed 
30 on the surface of viruses or bacteria. Upon binding to DC-SIGN, the antigens are 
internalized, processed and later presented on the surface of dendritic cells together with 
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costimulatory molecules. Mycobacteria also use DC-SIGN as a receptor to enter dendritic 
cells (G. De Libero and L. Mori, Nat Rev lmmunol 2005, 5:485-496). 
Glass slides printed with the immobilized PI and PIM1 - PIM6 were incubated with a DC-
5 SIGN solution in buffer at room temperature to allow DC-SIGN to bind to the immobilized 
PI Ms. Excess DC-SIGN was washed off and bound DC-SIGN was detected by incubation 
with a fluorescein-conjugated anti-DC-SIGN antibody. The difference in DC-SIGN binding 
affinity to the synthetic PIM compounds was assessed semi-quantitatively by monitoring 
the fluorescence intensity via a fluorescence scanner. Synthetic PIMs bind to DC-SIGN in 
10 a specific manner. Although both synthetic analogs of the most abundant PIM2 and PIM6 
are recognized by DC-SIGN, the larger synthetic oligosaccharides PIM5 and PIMs bound 
to DC-SIGN to a greater extent. This observation underlines the significance of the a-1,2-
mannose motif present in both PIMs and ManLAM structures. 
15 Adjuvant activity of P/Ms. An important feature of natural PIMs is their ability to induce a 
host cell immune response. To investigate immunostimulatory effects of these synthetic 
PIMs four C57BU6 mice per group were prime-boost immunized with the model antigen 
keyhole-limpet hemocyanin (KLH) covalently linked to PIM2 and PIM6 . As expected, 
immunization with the pure antigen KLH resulted in detectable anti-KLH antibody levels. 
20 Antibody production in the presence of the well-established adjuvants Freund's adjuvant, 
alum and CpG, increased substantially. In comparison, conjugation of PIM6 glycan to KLH 
also resulted in a marked increase of anti-KLH antibodies that was statistically significant 
for each serum dilution compared to KLH alone (Figure 2). To address the mechanism by 
which the increased antibody production after covalent attachment of PIM6 to KLH was 
25 caused, spleen cells of immunized mice were restimulated with KLH ex vivo and 
proliferation measured. Spleen cell proliferation of mice that had been immunized with 
KLH-PIM6 was significantly increased indicating that T cell priming was stimulated by PIM6 
glycan (Figure 4). It is also known that adjuvant properties not only depend on antibody 
production and T cell proliferation, but also on other T effector functions such as cytokine 
30 production. To this end, IFN-y production ofT cells was measured by ELl Spot analysis. 
The frequency of IFN-y producing T cells in spleen was determined upon restimulation of 
T cells with KLH. The ability ofT cells to produce IFN-y was increased in spleen cells of 
mice that had been immunized with KLH-PIM6 conjugate (Figure 5). The effect was even 
stronger than with the well-established adjuvants Freund's adjuvant, alum or CpG (CpG 
35 oligonucleotide ODN 1585, murine TLR9 ligand), which highlights the immunostimulatory 
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capacity of synthetic PIM6 glycan. Concanavalin A was used as a positive control since it 
serves as aT cell mitogen and stimulates all T cells to the same extent. 
Recognition of PIM6 by pattern recognition receptors on antigen-presenting cells might 
5 provide a danger signal, thereby facilitating enhanced uptake of the model antigen and 
increased expression of costimulatory molecules. The effect of PIM6 on T cell proliferation 
and T cell effector functions such as IFN-y production clearly indicates that antigen 
presentation by APCs and T cell activation are increased by PIM6 glycan. 
10 The synthetic PI and PIMs - PIM6 are suitable for conjugation with other appropriate 
surfaces such as fluorescent nanocrystals, beads or fluorophores to generate probes for 
cellular assays. Such tools may shed light on the mechanism by which PIM structures on 
Mtb can influence bacterial trafficking in host cells. The synthetic compounds can also be 
attached to affinity columns in search for proteins or enzymes in cell lysates that interact 
15 with PI Ms. Moreover, the synthetic PIMs can be used as substrates to explore 
biosynthetic pathways of the PI Ms. 
Synthetic PIMs are useful as antigens to elicit an immune response against Mtb as well as 
adjuvants in vivo. For these purposes, the synthetic compounds are conjugated to 
20 different antigens. 
Examples 
25 General procedures for glycosylations: Glycosylating agent and nucleophile were co-
evaporated with anhydrous toluene (3x) in vacuo and placed under high vacuum for at 
least 4 h. Glycosylations were performed without molecular sieves. Under argon 
atmosphere, the glycosylating agent and nucleophile mixtures were dissolved in a solvent 
at room temperature (rt) before being cooled to a desired temperature ,(ooc by ice-water 
30 bath, -1 ooc by ice-acetone bath, and -40°C by dry ice-acetonitrile bath). A promoter 
(TMSOTf or TBDMSOTf) was added to this reaction solution in one portion via syringe. 
After the reaction had finished, excess triethylamine (NEh) was added to quench the 
reaction at the reaction temperature. The reaction mixture was concentrated in vacuo and 
purified by flash silica column chromatography or directly used as a starting material in the 
35 next reaction. 
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(2-0-Benzoyl-3, 4-di-0-benzyl-6-0-triisopropylsilyl-a-o-mannopyranosyiH 1 ~6)-1-0-allyl-
2-0-napthylmethyl-3.4.5-tri-0-benzyl-o-myo-inositol (17): Following the general 
procedures for glycosylations, a glycosylation of mannosyl phosphate 10 (122 mg, 0.150 
mmol) and inositol 11 (86 mg, 0.136 mmol) promoted by TMSOTf (29 1-JL, 0.150 mmol) 
5 was carried out in toluene (4 ml) at -40°C for 2 h. After being quenched by NEh (60 1-JL), 
the reaction mixture was concentrated in vacuo and purified by flash silica column 
chromatography (cyclohexane I EtOAc) to obtain the title compound 17 in quantitative 
yield as a white solid. Rt 0.51 (cyclohexane I EtOAc = 4 : 1 ); [a]or.t.=- 6.8 (c = 1.0, CHCI3); 
b.p. = 130.5- 132°C; 1H NMR (300 MHz, CDCb) o 8.24- 8.15 (m, 2H), 7.92-7.78 (m, 
10 4H), 7.68-7.58 (m, 2H), 7.55- 7.44 (m, 4H), 7.44- 7.13 (m, 25H), 6.12-5.91 (m, 1 H), 
5.79 (dd, J = 1.9, 3.0, 1 H), 5.58 (d, J = 1.5, 1 H), 5.37- 5.15 (m, 2H), 5.10-4.60 (m, 
12H), 4.40-3.89 (m, 8H), 3.61 (brs, 2H), 3.52-3.24 (m, 3H), 1.20- 1.03 (m, 21 H); 
HRMS-MALDI (m/z): [M+Nar calculated for CnHaa012SiNa, 1255.5937; Found: 
1255.5911. 
15 
(2 -0-Benzoyl-3.4-di-0-benzyl-6-0-levun iloyl-a-o-man nopyranosyl)-( 1 ~6)-1-0-allyl-2 -0-
(2-0-acetyl-3.4.6-tri-0-benzyl-a-o-mannopyranosyl}-3,4,5-tri-0-benzyi-D-myo-inositol (21 ): 
Following the general procedures for glycosylations, a glycosylation of mannosyl 
phosphate 1 (225 mg, 0.217 mmol) and pseudodisaccharide 20 (238 mg, 0.347 mmol) 
20 promoted by TBDMSOTf (85 IJL, 0.370 mmol) was carried out in toluene (5 ml) at ooc for 
1 h. After being quenched by NEh (100 1-JL), the reaction mixture was concentrated in 
vacuo and purified by flash silica column chromatography (cyclohexane I EtOAc gradient) 
to obtain the title compound 21 (311.1 mg, 95%) as a colorless syrup. Rt 0.33 
(cycloh-exane I EtOAc = 7: 3); [a]0 r.t.= + 9.3 (c = 1.0, CHCI3); 1H NMR (600 MHz, CDCb) o 
25 8.11 -8.05 (m, 2H), 7.60- 7.54 (m, 1 H), 7.49-7.42 (m, 2H), 7.38-7.09 (m, 40H), 5.96 
- 5.85 (m, 1 H), 5.65 (dd, J = 2.1, 2.9, 1 H), 5.53 (d, J = 1.8, 1 H), 5.42 (dd, J = 2.0, 2.9, 1 H), 
5.23-5.17 (m, 1H), 5.12 (d, J= 1.8, 1H), 5.11-5.09 (m, 1H), 5.00-4.68 (m, 8H), 4.65-
4.25 (m, 9H), 4.20-3.78 (m, 12H), 3.51 (dd, J = 3.5, 10.8, 1 H), 3.36-3.23 (m, 4H), 2.74 
- 2.42 (m, 4H), 2.08 (s, 3H), 2.07 (s, 3H); HRMS-MALDI (m/z): [M+Nar calculated for 
30 C91H960 20Na, 1531.6387; Found: 1531.6372. 
(2 -0-Benzoyl-3, 4-di-0-benzyl-a-o-man nopyranosyl)-( 1 ~6)-1-0-a llyl-2 -0-(2-0-acetyl-
3.4, 6-tri-0-benzyl-a-o-mannopyranosyl}-3.4, 5-tri-0-benzyl-o-myo-inositol (8): A solution of 
trisaccharide 21 (840 mg, 0.556 mmol) and hydrazine acetate (256 mg, 2.782 mmol) in a 
35 mixture of CH2CI2 (30 ml) and MeOH (15 ml) was stirred at rt. After 4 h, although there 
was a small amount of the starting material 21 left, the reaction was quenched by adding 
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pyridine (15 ml) and acetone (15 ml) in order to avoid the reduction of the allyl group on 
the desired product by hydrazine acetate. The reaction mixture was concentrated in vacuo 
and purified by flash silica column chromatography (cyclohexane I EtOAc) to obtain the 
title compound 8 (698.9 mg, 89 %) as a colorless syrup. Rt 0.40 (cyclohexane I EtOAc = 7 
5 : 3); [a] 0 r.t.= + 14.1 (c = 1.0, CHCI3); 1H NMR (600 MHz, CDCI3) o 8.08- 8.03 (m, 2H), 
7.59- 7.53 (m, 1 H), 7.48- 7.41 (m, 2H), 7.38- 7.08 (m, 40H), 5.95- 5.83 (m, 1 H), 5.65 
(dd, J = 1.9, 3.1, 1 H), 5.54 (d, J = 1.8, 1 H), 5.46 (dd, J = 1.9, 3.0, 1 H), 5.22- 5.18 (m, 1 H), 
5.17 (d, J = 1.7, 1 H), 5.09 (dd, J = 1.4, 1 0.4, 1 H), 4.97-4.51 (m, 14H), 4.43-4.26 (m, 
3H), 4.18- 3. 76 (m, 1 OH), 3.55- 3.23 (m, 7H), 2.08 (s, 3H), 1.86 (brs, 1 H); HRMS-MALDI 
10 (m/z): [M+Nat calculated for C86H900 18Na, 1433.6019; Found: 1433.5996. 
1-0-AIIyl-2 -0-(2 I 3.4 I 6-tetra-0-benzyl-a-o-mannopyranosyl}-3.4 I 51 6-tetra-0-benzyl-o-mvo-
inositol (31 ): Following the general procedures for glycosylations, a glycosylation of 
mannosyl phosphate 1 (273.8 mg, 0.400 mmol) and inositol 23 (194.0 mg, 0.364 mmol) 
15 promoted by TMSOTf (76 IJL, 0.400 mmol) was carried out in EhO (8 ml) at -40°C for 
1.5 h. After being quenched by NEh (150 IJL), the reaction mixture was concentrated in 
vacuo and purified by flash silica column chromatography (cyclohexane I EtOAc) to obtain 
1-0-allyl-2 -0-(2-0-acetyl-3,4,6-tri-0-benzyl-a-o-mannopyranosyl)-3,4,5-tri-0-benzyl-6-0-
acetyi-D-myo-inositol 31p (266.0 mg, 70 %) as a colorless syrup. [a]0 r.t.= + 14.5 (c = 1.0, 
20 CHCI3); 1H NMR (300 MHz, CDCI3) o 7.49-7.07 (m, 30H), 5.93-5.70 (m, 1H), 5.57 (dd, 
J = 2.1, 2.7, 1 H), 5.46 (t, J = 10.0, 1 H), 5.28-5.21 (m, 2H), 5.21 -5.11 (m, 2H), 4.93-
4.70 (m, 6H), 4.68-4.53 (m, 4H), 4.47-4.23 (m, 3H), 4.21 -4.04 (m, 2H), 4.03-3.84 
(m, 4H), 3.59- 3.18 (m, 5H), 2.17 - 2.10 (m, 3H), 1.97 (s, 3H); HRMS-MALDI (m/z): 
[M+Nat calculated for Ca1Ha60 13Na, 1029.4396; Found: 1029.4400. 
25 
To a solution of pseudodisaccharide 31p (266 mg, 0.288 mmol) in .a mixture of CH2CI2 
(1 mL) and MeOH (3 ml), a solution of NaOMe in MeOH (1.150 IJL of 0.288 M, 0.180 
mmol, freshly prepared from Na(s) and MeOH) was added at rt. The reaction was stirred 
at rt for 2 d, concentrated in vacuo, and filtered through a short plug of silica gel to obtain 
30 a yellow syrup. A solution of this crude product and BnBr (121 IJL, 1.018 mmol) in DMF 
(8 ml) was cooled to ooc and NaH (60% in mineral oil, 40.7 mg, 1.018 mmol) was added. 
The reaction mixture was allowed to warm to rt. After 5 h at rt, the reaction was quenched 
by carefully adding MeOH (1 ml) dropwise. The reaction mixture was diluted with EtOAc 
(20 ml), washed with water (2x) and brine, dried over MgS04 , and concentrated in vacuo. 
35 The crude product was purified by flash silica column chromatography (cyclohexane I 
EtOAc) to obtain the title compound 31 in quantitative yield (2 steps) as a colorless syrup. 
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NMR spectra are the same as reported in literature (C.J.J. Elie et al., Tetrahedron 1989, 
45:34 77 -3486). 
(213.4~6-Tetra-0-benzyl-a--mannpyransyi)-(1~6)-1-0-allyl-2-0-(213.416-tetra-0-
5 benzyl-a--mannpyransyl)-3.4~5-tri-0-benzyl--mv-insitl (32): To a solution of 
pseudotrisaccharide 8 (59.7 mg, 0.042 mmol) in a mixture of THF (1 mL) and MeOH 
(1 mL) a solution of NaOMe in MeOH (168 IJL of 0.250 M, 0.042 mmol, freshly prepared 
from Na(s) and MeOH) was added at rt. The reaction was stirred at rt for 3d and 
neutralized with acid resin (methanol washed Amberlite IR-120). The resin was filtered off 
10 and the reaction solution was concentrated in vacuo and placed under high vacuum for 
4 h. A solution of this crude product and BnBr (20 IJL, 0.168 mmol) in DMF (4 mL) was 
cooled to ooc and NaH (60% in mineral oil, 7 mg, 0.168 mmol) was added. The reaction 
mixture was allowed to warm to rt. After 12 h at rt, the reaction mixture was transferred to 
a separatory funnel and carefully quenched by minimum amount of MeOH and water (1 0 
15 mL). The reaction mixture was extracted with EtOAc (3 x 10 mL). The combined organic 
layer was washed with brine, dried over Na2S04, and concentrated in vacuo. The crude 
product was purified by flash silica column chromatography (cyclohexane I EtOAc) to 
obtain the title compound 32 (58 mg, 90 %, 2 steps) as a colorless syrup. Rt 0.27 
(hexanes I EtOAc = 3: 1); [a]0 r.t.= + 26.4 (c = 1.8, CHCI3); 1H NMR (500 MHz, CDCI3) o 
20 7.41-6.96 (m, 55H), 5.70 (ddd, J= 5.5, 10.6, 22.7, 1H), 5.48 (d, J= 1.7, 1H}, 5.22 (d, J= 
1.4, 1 H), 5.21 - 5.16 (m, 1 H), 5.08-5.04 (m, 1 H), 4.93-4.25 (m, 22H), 4.20-3.72 (m, 
13H}, 3.49 (dd, J = 3.7, 10.7, 1H), 3.42-3.07 (m, 6H); HRMS-MALDI (m/z): [M+Nar 
calculated for C98H1020 16Na, 1557.7030; Found: 1557.7030. 
25 (2131416-Tetra-0-benzyl-a--mannpyransyl)-(1~6)-(213141-tri-0-benzyl-a--mann-
pyranosyiH 1 ~6)-1-0-allyl-2 -0-(2 I 3 I 41 6-tetra-0-benzyl-a-o-man n opyranosyl)-3.4! 5:.tri-O-
benzyl-o-mvo-inositol (33): Following the general procedures for glycosylations, a 
glycosylation of mannosyl phosphate 1 (54.0 mg, 0.079 mmol) and pseudotrisaccharide 8 
(70.0 mg, 0.049 mmol) promoted by TMSOTf (12 IJL, 0.064 mmol) was carried out in 
30 CH2CI2 (3 mL) at -1 ooc for 1 h. After being quenched by NEh (40 IJL}, the reaction mixture 
was concentrated in vacuo. To a solution of this crude product in THF (2 mL}, a solution of 
NaOMe in MeOH (2.00 mL of 0.250 M, 0.500 mmol, freshly prepared from Na(s) and 
MeOH) was added at rt. The reaction was stirred at 50°C for 12 h and neutralized with 
acid resin (methanol washed Amberlite IR-120). The reaction mixture was filtered through 
35 a short plug of silica gel, concentrated in vacuo and placed under high vacuum for 4 h. A 
solution of this crude product and BnBr (59 IJL, 0.496 mmol) in DMF (4 mL) was cooled to 
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ooc and NaH (60% in mineral oil, 20 mg, 0.496 mmol) was added. The reaction mixture 
was allowed to warm to rt. After 12 h at rt, the reaction mixture was transferred to a 
separatory funnel and carefully quenched by minimum amount of MeOH and water (1 0 
ml). The reaction mixture was extracted with EtOAc (3 x 10 ml). The combined organic 
5 layer was washed with brine, dried over Na2S04, and concentrated in vacuo. The crude 
product was purified by general procedures for glycosylations flash silica column 
chromatography (cyclohexane I EtOAc) to obtain the title compound 33 (86.5 mg, 89 %, 3 
steps) as a colorless syrup. Rt 0.27 (cyclohexane I EtOAc = 4 : 1 ); [a]0 r.t.= + 35.6 (c = 1.0, 
CHCI3); 1H NMR (300 MHz, CDCI3) o 7.50-7.09 (m, 70H), 5.77 (ddd, J = 5.4, 10.6, 22.5, 
10 1 H), 5.50 (d, J = 1.1, 1 H), 5.29 (brs, 1.5H), 5.23 (d, J = 1.3, 0.5H), 5.15 (d, J = 0.9, 0.5H), 
5.11 (brs, 1.5H), 5.08- 4. 76 (m, 7H), 4. 76- 4.26 (m, 22H), 4.26- 3.80 (m, 15H), 3.62-
3.13 (m, 1 OH); ESI-MS (m/z): [M+NH4]1+ calculated for C125H134N021 , 1984 .. 9; Found: 
1984.4 as a dominant peak. 
15 (2. 3.4.6-Tetra-0-benzyl-a-o-mannopyranosyiH 1 ~6}-(2. 3.4. -tri-0-benzyl-a-o-manno-
pyranosyl)-( 1 ~6)-(2. 3.4. -tri-0-benzyl-a-o-mannopyranosyl)-( 1 ~6)-1-0-allyl-2-0-(2.3.4. 6-
tetra-0-benzyl-a-o-mannopyranosyl)-3.4.5-tri-0-benzyl-o-myo-inositol (34): Following the 
general procedures for glycosylations, a glycosylation of mannosyl imidate 2 (1 02.0 mg, 
0.094 mmol) and pseudotrisaccharide 8 (11 0.0 mg, 0.078 mmol) promoted by TMSOTf 
20 (1.8 IJL, 0.008 mmol) was carried out in CH2CI2 (3 ml) at -1 ooc for 1 h. After being 
quenched by NEh (1 0 1-JL), the reaction mixture was concentrated in vacuo. To a solution 
of this crude product in THF (2 ml), a solution of NaOMe in MeOH (3.1 ml of 0.250 M, 
0.780 mmol, freshly prepared from Na(s) and MeOH) was added at rt. The reaction was 
stirred at 60°C for 18 hand neutralized with acid resin (methanol washed Amberlite IR-
25 120). The reaction mixture was filtered through a short plug of silica gel, concentrated in 
vacuo and placed under high vacuum for 4 h. A solution of this crude product and BnBr 
(52 IJL, 0.441 mmol) in DMF (4 ml) was cooled to ooc and NaH (60% in mineral oil, 23.5 
mg, 0.588 mmol) was added. The reaction mixture was allowed to warm tort. After 12 hat 
rt, the reaction mixture was transferred to a separatory funnel and carefully quenched by 
30 minimum amount of MeOH and water (1 0 ml). The reaction mixture was extracted with 
EtOAc (3 x 10 ml). The combined organic layer was washed with brine, dried over 
Na2S04, and concentrated in vacuo. The crude product was purified by flash silica column 
chromatography (cyclohexane I EtOAc) to obtain the title compound 34 (166.4 mg, 89 %, 
3 steps) as a colorless syrup. Rt 0.30 (cyclohexane I EtOAc = 7 : 3); [a]or.t.= + 38.7 (c = 
35 1.0, CHCI3); 1H NMR (500 MHz, CDCI3) o 7.47-7.05 (m, 85H), 5.82- 5.68 (m, 1 H), 5.45 
(brs, 1 H), 5.24 (brs, 1.5H), 5.21 (brs, 0.5H), 5.12 (brs, 0.5H), 5.09 (brs, 1.5H), 5.07-4.76 
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(m, 9H), 4.75-4.30 (m, 27H), 4.22-3.79 (m, 18H), 3.69-3.48 (m, 5H), 3.46- 3.09 (m, 
8H); HRMS-MALDI (m/z): [M+Nar calculated for C152H1580 26Na, 2422.0934; Found: 
2422.0995. 
5 (21 3.416-T etra-0-benzyl-a-o-mannopyranosyl)-( 1 ~2)-(3.4 1 6-tri-0-benzyl-a-o-man no-
pyranosyl}-( 1 ~6)-(2 13.41 -tri-0-benzyl-a-o-mannopyranosyl)-( 1---+6)-(21 3141 -tri-0-benzyl-a-
o-mannopyranosyl}-( 1 ~6)-1-0-allyl-2 -0-(2 13141 6-tetra-0-benzyl-a-o-mannopyranosyl}-
3.4~5-tri-0-benzyl--my-insitl) (35): Following the general procedures for 
glycosylations, a glycosylation of mannosyl imidate 3 (128.0 mg, 0.085 mmol) and 
10 pseudotrisaccharide 8 (100.0 mg, 0.071 mmol) promoted by TMSOTf (1.61JL, 0.007 
mmol) was carried out in CH2Cb (4 ml) at -10°C for 1 h. After being quenched by NEts 
(1 0 IJL), the reaction mixture was concentrated in vacuo. To a solution of this crude 
product in THF (2 ml), a solution of NaOMe in MeOH (2.8 ml of 0.250 M, 0.710 mmol, 
freshly prepared from Na(s) and MeOH) was added at rt. The reaction was stirred at 60°C 
15 for 12 hand neutralized with acid resin (methanol washed Amberlite IR-120). The reaction 
mixture was filtered through a short plug of silica gel, concentrated in vacuo and placed 
under high vacuum for 4 h. A solution of this crude product and BnBr (84 IJL, 0.709 mmol) 
in DMF (4 ml) was cooled to ooc and NaH (60% in mineral oil, 28.3 mg, 0.709 mmol) was 
added. The reaction mixture was allowed to warm to rt. After 16 h at rt, the reaction 
20 mixture was transferred to a separatory funnel and carefully quenched by minimum 
amount of MeOH and water (1 0 ml). The reaction mixture was extracted with EtOAc (3 x 
10 ml). The combined organic layer was washed with brine, dried over Na2S04, and 
concentrated in vacuo. The crude product was purified by flash silica column 
chromatography (cyclohexane I EtOAc) to obtain the title compound 35 (145.0 mg, 73 %, 
25 · 3 steps) as a colorless syrup. Rt 0.56 (cyclohexane I EtOAc = 7: 3); [a]0 r.t.= + 38.5 (c = 
1.0, CHCI3); 1H NMR (500 MHz, CDCI3) o 7.50-7.06 (m, 100H), 5.77 (ddd, J = 5.5, 10.6, 
22.6, 1 H), 5.49 (d, J = 1.4, 1 H), 5.29- 5.25 (m, 1.5H), 5.25- 5.21 (m, 1.5H), 5.15- 5.10 
(m, 1 H), 5.08-4.87 (m, 8H), 4.86-4.77 (m, 3H), 4.76-4.33 (m, 32H), 4.25-4.03 (m, 
6H), 4.03- 3.82 (m, 16H), 3.82- 3.53 (m, 4H), 3.53- 3.11 (m, 11 H); HRMS-MALDI (m/z): 
30 [M+Nat calculated for C179H1se031Na, 2854.2870; Found: 2854.2804. 
(2 I 3.416-T etra-0-benzyl-a-o-mannopyranosyl)-( 1 ~2)-(3.41 6-tri-0-benzyl-a-o-manno-
pyranosyl)-( 1 ~2)-(3.4 I 6-tri-0-benzyl-a-o-ma n nopyranosyl}-( 1---+6)-(2 13141 -tri-0-benzyl-a-o-
mannopyranosyl)-( 1 ~6)-(21 3.41 -tri-0-benzyl-a-o-mannopyranosyl)-( 1 ~6)-1-0-allyl-2-0-
35 (2131416-tetra-0-benzyl-a-o-mannopyranosyl}-31415-tri-0-benzyl-o-myo-inositol) (36): 
Following the general procedures for glycosylations, a glycosylation of mannosyl imidate 4 
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(164.0 mg, 0.084 mmol) and pseudotrisaccharide 8 (99.0 mg, 0.070 mmol) promoted by 
TMSOTf (1.6 IJL, 0.007 mmol) was carried out in CH2CI2 (6 ml) at ooc for 1 h. After being 
quenched by NEt3 (10 IJL), the reaction mixture was concentrated in vacuo and purified by 
recycling size exclusion HPLC (eluent = 100% CHCb) to obtain (2-0-acetyl-3,4,6-tri-0-
5 benzyl-a-o-mannopyranosyl)-(1--+2)-{3,4,6-tri-0-benzyl-a-o-mannopyranosyl)-(1--+2)-
(3,4, 6-tri-0-benzyl-a-o-mannopyranosyl)-( 1--+6)-(2-0-benzoyl-3, 4, -di-0-benzyl-a-o-
mannopyranosyl)-( 1--+6)-(2-0-benzoyl-3,4, -di-0-benzyl-a-o-mannopyranosyl)-( 1--+6)-1-0-
allyi-2-0-(2-0-acetyl-3,4,6-tri-O-benzyl-a-o-mannopyranosyl)-3,4,5-tri-O-benzyl-o-myo-
inositol) 36p (143.0 mg, 64 %) as a colorless syrup. The remaining pseudotrisaccharide 
10 starting material 8 was also recovered (27.5 mg, 28%) as a colorless syrup. Rt 0.44 
(cyclohexane I EtOAc = 7: 3); [a]0 r.t = + 25.9 (c = 1.0, CHCI3); 1H NMR (600 MHz, CDCI3) 
o 8.17- 8.01 {m, 4H), 7.50- 6.87 (m, 101 H), 5.90 (ddd, J = 5. 7, 1 0.5, 22.8, 1 H), 5. 76 (dd, 
J = 2.0, 2.9, 1 H), 5.74 (dd, J = 2.1, 2.9, 1 H), 5.56 (dd, J = 1.9, 3.2, 1 H), 5.54 {d, J = 1.7, 
1 H), 5.42 (dd, J = 2.0, 3.0, 1 H), 5.26 (d, J = 1.6, 1 H), 5.24- 5.19 {m, 1 H), 5.16 (d, J = 1.6, 
15 1 H), 5.10 (s, 1.5H), 5.09- 5.08 (m, 0.5H), 5.05- 4.68 (m, 15H}, 4.68- 4.61 {m, 3H}, 4.60 
-4.49 {m, 10H}, 4.48-4.21 (m, 12H), 4.21-4.07 (m, 6H}, 4.07-3.85 {m, 14H), 3.85-
3.75 (m, 4H), 3.63 (m, 3H), 3.46 (m, 4H), 3.40- 3.26 (m, 7H), 3.23- 3.12 (m, 2H}, 2.11 
(s, 3H), 2.05 (s, 3H); ESI-MS (m/z): [M+2(NH4}]2+ calculated for C196H210N204o2+, 1615.7; 
Found: 1615.5 as a dominant peak. 
20 
To a solution of pseudoheptasaccharide 36p (120 mg, 0.037 mmol) in THF (3 ml) a 
solution of NaOMe in MeOH (1.50 ml of 0.250 M, 0.375 mmol, freshly prepared from 
Na(s) and MeOH) was added at rt. The reaction was stirred at 50°C for 18 hand 
neutralized with acid resin (methanol washed Amberlite IR-120). The reaction mixture was 
25 filtered through a short plug of silica gel, concentrated in vacuo and placed under high 
vacuum for 4 h. A solution of this crude product and BnBr (44.5 IJL, 0.375 mmol) in DMF 
(4 ml) was cooled to ooc and NaH (60% in mineral oil, 15.0 mg, 0.375 mmol) was added. 
The reaction mixture was allowed to warm to rt. After 18 h at rt, the reaction mixture was 
transferred to a separatory funnel and carefully quenched by minimum amount of MeOH 
30 and water (1 0 ml). The reaction mixture was extracted with EtOAc (3 x 10 ml). The 
combined organic layer was washed with brine, dried over Na2S04, and concentrated in 
vacuo. The crude product was purified by flash silica column chromatography 
(cyclohexane I EtOAc) to obtain the title compound 36 (118.7 mg, 97 %, 2 steps) as a 
colorless syrup. Rt 0.34 (cyclohexane I EtOAc = 7: 3); [a]0 r.t.= + 35.0 (c = 1.0, CHCI3); 1H 
35 NMR (300 MHz, CDCI3) o 7.46- 7.03 {m, 115H), 5.49 (brs, 1 H), 5.29- 5.17 {m, 3H}, 5.04 
-4.78 (m, 9H), 4.78-3.99 (m, 46H), 3.99-3.50 {m, 29H), 3.49-3.15 (m, 6H), 1.70 (brs, 
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1 H); HRMS-MALDI (m/z): [M+Nat calculated for C2o3H21o03sNa, 3246.4494; Found: 
3246.4406. 
General procedures to remove allyl protecting group by the lr complex to prepare 
5 compounds 38 - 43: Each oligosaccharide starting material (31 - 36) was coevaporated 
with toluene (3x) and placed under high vacuum for 4 h prior to the reaction. Under an 
argon atmosphere, a solution of lr{(COD)[PHJ(CsHshh}PF6 (cat. i.e. 0.2 equiv.) in THF 
(distilled over sodium) was degassed by vacuum and gassed with H2 (g) balloon (- 5 
cycles). The reaction was stirred under H2 atmosphere at rt for 5 min before the solution 
10 was degassed by vacuum and gassed with argon(- 5 cycles). To this reaction flask, a 
solution of an allyl protected compound (31 - 36, 1 equiv., - 0.05 mmol) in THF (1 ml) 
was added via syringe in one portion at rt. The reaction was stirred at rt for 2 h before 
concentrated in vacuo. The completed isomerization of the terminal allyl group was 
verified by 1H NMR. The crude product was treated with p-TsOH (0.1 equiv. for 31, 10 
15 equiv. for 32- 36) in a mixture of CH2CI2 and MeOH (3: 1, total volume= 2.66 ml) for 
12 h at rt. The reaction solution was diluted with EtOAc (20 ml), washed with saturated 
aqueous NaHC03 (3x) and brine, dried over Na2S04 and concentrated in vacuo. The 
crude product was purified by flash silica column chromatography (cyclohexane I EtOAc) 
to obtain the title compounds 38 (quant.); 39 (71 %); 40 (81 %); 41 (79%); 42 (87%); or 43 
20 (89%) as colorless syrup. 
General procedures for phosphorvlations to prepare the protected phosphodiesters 
45(a-g): Each oligosaccharide (37 - 43) was combined with the 6-(S-benzyl)thiohexyl H-
phosphonate 44, coevaporated with pyridine (3x) and placed under high vacuum for 4 h 
25 prior to the reaction. To a solution of an oligosaccharide backbone (37- 43, - 0.03 mmol) 
and 44 (0.15 mmol) in pyridine (2 ml), PivCI (0.3 mmol) was added at rt. After 3h at rt, 
iodine (0.21 mmol) in a mixture of pyridine and water (1 0 : 1, 300 !JL total volume) was 
added to the reaction solution at rt and stirred for 1 h. The reaction mixture was diluted 
with CH2CI2 (1 0 ml) and Na2S203 (20 ml of 1M) and extracted with CH2CI2 (3 x 10 ml). 
30 The combined organic layer was dried over Na2S04(s), concentrated in vacuo, purified by 
flash silica column chromatography (CH2CI21 MeOH gradient, silica gel was neutralized 
with 1% NEt3 in CH2CI2 prior to use) and size exclusion column chromatography 
(Sephadex LH-20, MeOH I CH2CI2 1 NEh = 100: 100: 0.05) to obtain compounds 
45(a-g) as a colorless syrup (90% to quant.) 
35 
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General procedures for Birch reductions to prepare PI and PIM1 - PIM6: At -78°C (dry ice I 
acetone bath}, ammonia was condensed into a solution of a phosphodiester 45 (- 0.02 
mmol) in a mixture of THF (25 ml) and t-BuOH (0.5 mL). Small pieces of Na(s) was 
added to the reaction to generate a stable dark blue solution for at least 30 min and 
5 MeOH was added to the reaction solution. Then, small pieces of Na(s) was again added 
to the reaction to generate a stable dark blue solution for at least 30 min and MeOH was 
added to the reaction solution. The reaction was allowed to slowly warm tort by removing 
the dry ice I acetone bath and most of the remaining ammonia in the reaction solution was 
blown off by argon stream. The reaction solution was concentrated in vacuo, re-dissolved 
10 in water, neutralized with a small amount of acid resin (methanol washed Amberlite IR-
120). The resin was filtered off and the mother liquor was concentrated in vacuo, re-
dissolved in water, and extracted with CHCb to remove the less polar partially 
debenzylated side products. The volume of the aqueous layer was decreased by 
lyophilzation and the aqueous solution was dialysed to afford the final product PI, PIM1, 
15 PIM2, PIM3, PIM4 , PIM5, or PIM6 . 
PI: White solid (65%); 1H NMR (300 MHz, 0 20) o 4.25 (t, J = 2. 7, 1 H), 4.01 - 3.83 (m, 
3H), 3.81 -3.47 (m, 4H), 3.33 (t, J = 9.3, 1 H), 2.81 - 2.74 (m, 0.2H), 2.42 (t, 1.8H), 1.74-
1.51 (m, 4H), 1.49- 1.34 (m, 4H); 31 P NMR (121 MHz, COCb) o 0.79; ESI-MS (m/z): 
20 [M-Hr calculated for C12H24o9ps·. 375.0; Found: 374.6 as a dominant peak. 
PIM1: White solid (43%); 1H NMR (300 MHz, 0 20) o 5.13 (d, J = 1.5, 1 H), 4.32-4.25 (m, 
1 H), 4.13-4.06 (m, 1 H), 4.04- 3.53 (m, 12H), 3.31 (t, J = 8.8, 1 H), 2.88- 2.68 (m, 0.5H), 
2.54 (t, J = 7.1, 1.5H), 1.76- 1.51 (m, 4H), 1.50- 1.29 (m, 4H); 13C NMR (75 MHz, 0 20) o 
25 101.69, 79.27, 76.46, 76.41, 74.43, 72.97, 72.69, 72.08, 72.03, 70.60, 70.37, 70.25, 
66.87, 66.68, 66.63, 61.12, 38.42, 33.18, 30.02, 29.97, 29.96, 28.53, 27.51, 27.35, 24.77, 
24.60, 23.93; 31 P NMR (121 MHz, COCI3) o 0.86; HRMS-ESI (m/z): [M-Hrcalculated for 
C1aH34014PS1-, 537.1412; Found: 537.1403. 
30 PIM2 : White solid (56%); 1H NMR (500 MHz, 0 20) o 5.04 (s, 1 H), 5.02 (s, 1 H), 4.19 (s, 
1 H), 4.06-3.42 (m, 20H), 3.23 (t, J = 9.2, 1 H), 2.65 (t, J = 7.2, 2H), 1.65- 1.45 (m, 4H), 
1.44-1.22 (m, 4H); 13C NMR (125 MHz, 0 20) o 101.62, 101.60, 78.96, 78.34, 78.29, 
76.68, 73.26, 72.99, 72.84, 70.61, 70.41, 70.25, 70.12, 66.89, 66. 79, 66.53, 61.14, 60.92, 
38.41, 30.17, 30.12, 28.54, 27.48, 24.85; 31 P NMR (121 MHz, COCI3) o 0.48; HRMS-ESI 
35 (m/z): [MS-SM-2Hf- calculated for C4aHa603sP2S/-, 698.1863; Found: 698.1862. 
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PIM3: White solid (91 %); 1 H NMR (600 MHz, 0 20) o 5.15 (s, 1 H), 5.10 (s, 1 H), 4.90 (s, 
1 H), 4.30 (d, J = 1.9, 1 H), 4.21 -4.04 (m, 4H), 4.03- 3.90 (m, 5H), 3.90- 3.72 (m, 10H), 
3.64 (m, 7H), 3.36 (t, J = 9.1, 1 H), 2.77 (t, J = 7.2, 1.7H), 2.54 (t, J = 7.1, 0.3H), 1.80-
1.58 (m, 4H), 1.42 (brs, 4H); 13C NMR (150 MHz, 0 20) o 104.27, 104.12, 102.26, 81.37, 
5 81.10, 81.06, 79.29, 79.26, 75.68, 75.51, 75.48, 75.43, 73.70, 73.36, 73.31, 73.15, 72.93, 
72.73, 72.59, 69.53, 69.39, 69.36, 69.33, 69.28, 69.24, 68.33, 63.69, 63.66, 40.95, 32.60, 
32.56, 32.45, 31.02, 30.12, 29.93, 27.32, 27.15; 31 P NMR (121 MHz, COCI3) o 0.33; 
HRMS-ESI (m/z): [M-H+2Nat calculated for C3oHs4024PSNa2+, 907.2253; Found: 
907.2244. 
10 
PIM4: White solid (65%); 1 H NMR (600 MHz, 0 20) o 5.17 (d, J = 1.8, 1 H), 5.12 (d, J = 1.5, 
1 H), 4.90 (d, J = 1.6, 1 H), 4.90 (d, J = 1.6, 1 H), 4.35-4.28 (m, 1 H), 4.22-4.16 (m, 1 H), 
4.15 (dd, J = 1.7, 3.2, 1 H), 4.12 (dd, J = 1.9, 3.3, 1 H), 4.10-4.06 (m, 1 H), 4.03-3.89 (m, 
8H), 3.89-3.73 (m, 13H), 3.73-3.55 (m, 8H), 3.37 (td, J = 3.3, 9.2, 1H), 2.84-2.72 (m, 
15 1.5H), 2.56 (t, J = 7.2, 0.5H), 1.80- 1.56 (m, 4H), 1.52- 1.36 (m, 4H); 13C NMR (150 
MHz, 0 20) o 104.26, 104.08, 102.22, 102.07, 81.40, 81.36, 81.02, 80.97, 79.09, 79.05, 
75.65, 75.46, 75.42, 73.56, 73.47, 73.38, 73.26, 73.09, 72.89, 72.71, 72.69, 72.64, 72.56, 
69.47, 69.36, 69.35, 69.22, 69.00, 68.96, 68.38, 68.09, 63.66, 63.61, 40.88, 35.63, 32.62, 
32.58, 31.01, 29.94, 29.78, 27.31, 27.14, 26.40; 31 P NMR (121 MHz, COCI3) o -0.49, 
20 -0.48; HRMS-ESI (m/z): [M-Hr calculated for C3sHs4029ps-, 1 023.2997; Found: 
1023.2990. 
PIM5: White solid (88%); 1H NMR (500 MHz, 0 20) o 5.05 (s, 1 H), 5.02 (s, 1 H), 5.01 (s, 
1 H), 4.92 (s, 1 H), 4. 79 (s, 1 H), 4.20 (s, 1 H), 4.11 - 3.44 (m, 39H), 3.26 (t, J = 9.1, 1 H), 
25 2.67 (t, J = 7.2, 1.5H), 2.41 (t, J = 7.3, 0.4H), 1.66- 1.47 (m, 4H), 1.32 (m, 4H); 13C NMR 
(125 MHz, 0 20) o 102.48, 101.78, 101.61, 99.80, 98.33, 78.93, 78.48, 78.43, 76.64, 
76.59, 73.44, 73.17, 72.99, 71.33, 71.05, 71.00, 70.91, 70.62, 70.56, 70.45, 70.42, 70.25, 
70.20, 70.18, 70.09, 67.19, 67.15, 66.87, 66.84, 66.73, 66.53, 66.49, 66.20, 65.61, 61.37, 
61.18, 61.14, 38.40, 33.17, 30.16, 30.11, 28.54, 27.47, 27.31, 24.85, 24.67, 23.94; 31 P 
30 NMR (121 MHz, COCb) o 0.38, 0.33; HRMS-ESI (m/z): [M-H+2Nat calculated for 
C42H14034PSNa2+, 1231.3322; Found: 1231.3310. 
PIM6: White solid (52%); 1H NMR (500 MHz, 0 20) o 5.16 (d, J = 1.1, 1 H), 5.04 (s, 1 H), 
4.99 (s, 1H), 4.98 (s, 1H), 4.91 (d, J= 1.4, 1H), 4.77 (s, 1H), 4.18 (s, 1H), 4.10-3.91 (m, 
35 5H), 3.90- 3.40 (m, 37H), 3.24 (t, J = 9.1, 1 H), 2.65 (t, J = 7.3, 1 H), 2.43 (t, J = 7.3, 0.3 
H), 2.27- 2.21 (m, 0.15H), 1.69- 1.36 (m, 4H), 1.30 (s, 4H); 13C NMR (125 MHz, 0 20) o 
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102.43, 101.78, 101.61, 100.85, 99.81, 98.41, 78.99, 78.94, 78.90, 78.69, 78.49, 78.44, 
76.65, 76.60, 73.46, 73.18, 72.98, 71.39, 71.01, 70.93, 70.62, 70.56, 70.46, 70.42, 70.24, 
70.20, 70.17, 70.09, 67.31, 67.17, 67.06, 66.87, 66.82, 66.71, 66.54, 66.49, 66.23, 65.57, 
61.35, 61.29, 61.16, 61.14, 38.40, 33.17, 30.16, 30.11, 28.54, 27.48, 27.31, 24.84, 24.67, 
5 23.93; 31 P NMR (121 MHz, CDCI3) iS -0.50, -0.47; HRMS-ESI (m/z): [M-Hr calculated for 
C4aHa4039ps-, 1347.4054; Found: 1347.4049. 
Immunization of mice and detection of anti-KLH antibody levels in sera: Preparation of 
keyhole limpet hemocyanin (KLH) in complete/incomplete Freund's adjuvant was 
10 performed by mixing KLH with Freund's adjuvant in a 1:1 volume ratio. For coupling of 
PIM6 to KLH, PIM6 was incubated with Tris(2-carboxyethyl)phosphine HCI (TCEP) (to 
reduce disulfide bonds) in equal molar ratio for one hour at rt. A molar excess of PIMs was 
then coupled to KLH using the lmject® Maleimide Activated mcKLH Kit (Pierce, Rockford, 
IL) according to manufacturer's instructions. PIM6-KLH conjugate was purified by gel 
15 filtration chromatography and the protein concentration in the eluate was determined by 
measuring the absorption at a wavelength of 280 nm. 
Female C57BU6 mice (6-8 weeks old) were housed in the HCI rodent center, ETH ZOrich, 
and were provided food and water ad libitum. On day 0 four mice per group were s.c. 
immunized with KLH alone (group 1 ), KLH in complete Freund's adjuvant (group 2), KLH 
20 with alum (group 3), KLH with CpG (group 4) or KLH coupled to PIM6 (group 5). On 
day 10, mice received a boost immunization with KLH alone (group 1 ), KLH in incomplete 
Freund's adjuvant (group 2), KLH with alum (group 3), KLH with CpG (group 4) or KLH 
coupled to PIM6 (group 5). The amount of KLH was adjusted to 50 IJg per mouse and 
immunization. On day 17, blood was taken from the saphenous vein and serum was 
25 separated from the clotted blood by centrifugation. All animal experiments were in 
accordance with local Animal Ethics Committee regulations. 
Levels of anti-KLH antibodies in sera of immunized mice were measured by ELISA: 
Microlon microplates (Greiner, Frickenhausen, Germany) were coated with 10 IJg/mL KLH 
in 0.05 M Na2C03 buffer (pH 9.6) at 4 oc overnight. After blocking with 1 % BSA/PBS for 
30 two hours at rt and washing with 0.05 % Tween-20/PBS plates were incubated with serial 
dilutions of sera (diluted in 0.1 % BSA/PBS) for two hours. Plates were then washed three 
times with 0.05 % Tween-20/PBS and incubated with HRP-conjugated goat-anti-mouse 
lgG+A+M antibody in a dilution of 1:1000 (Invitrogen, Basel, Switzerland). Detection was 
performed by using the 3,3',5,5'-Tetramethylbenzidine Liquid Substrate System (Sigma-
35 Aldrich, Buchs, Switzerland) according to manufacturer's instructions. Results are shown 
in Figures 2 and 3. 
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T cell proliferation and ELl Spot analysis. On day 2a after the first immunization, mice were 
sacrificed and spleens were removed. RBCs were lysed by adding hypotonic ammonium 
chloride solution. Single cell suspensions were cultivated at 2 x 1 as cells per well in 96-
5 well plates for 24 h in the presence of medium or KLH (1 a IJg/ml) for restimulation ofT 
cells ex vivo. Proliferation of spleen cells was measured using the CeiiTiter 96® AQueous 
One Solution Cell Proliferation Assay (Promega, Madison, WI) according to the 
manufacturer's instructions. Results are shown in Figure 4. 
ELl Spot analysis was performed on day 2a after the first immunization using a mouse 
1 a IFN-y ELlS pot Kit (R&D Systems, Minneapolis, MN). Briefly, 2 x 1 as spleen cells per well 
were stimulated for 24 h in the presence of medium, KLH (1 a IJg/ml) or the T cell mitogen 
concanavalin A (ConA, 1 a IJg/ml). Spot development was performed according to the 
manufacturer's instructions and the number of spots was determined using an ELl Spot 
reader (AID, Stra~berg, Germany). Results are shown in Figure 5. 
15 
2a 
Statistical analysis. Statistical analyses were performed applying unpaired Student's t-test. 





1. A compound of formula (I) 
(I) 
5 wherein 
RA isH, a residue of formula (II}, (Ill), (IV}, M or (VI) 
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HO 
H~O HO .Q 
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.JVVVVVV>w (VI ) 
and R8 is -(CH2)n-X wherein n is between 2 and 10 or -(CH2CH20)mCH2CH2X wherein m 
is between 1 and 5, and X is a reactive functional group, a protein, a fluorescent probe or 
5 a solid phase. 
10 
2. The compound according to claim 1 wherein R8 is -(CH2)n-X. 
3. The compound according to claim 2 wherein R8 is -(CH2)n-X wherein n is 4, 5 or 6. 
4. The compound according to claim 1 wherein R8 is -(CH2CH20)mCH2CH2X wherein m 
is between 1 and 5. 
5. The compound according to claim 1 wherein X is a functional group selected from a 
15 sulfhydryl group (-SH), a maleimido function of formula (VII) 
20 
_)" );-l! (VII) 
0 
an amino group, and an optionally activated carboxyl group. 
6. The compound according to claim 5 wherein X is the sulfhydryl group. 
7. The compound according to claim 1 wherein X is a protein. 
8. The compound according to claim 1 wherein X is a fluorescent probe. 
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9. The compound according to claim 1 wherein X is a solid phase. 
10. The compound according to claim 1 wherein R8 is -(CH2)n-X, n is 6 and X is a 
5 sulfhydryl group. 
10 
11. The compound according to claim 10 of formula 
12. The compound according to claim 10 of formula 
H~OH HO .o 
HO 
PIM6 
H~O HO .o 
HO 
H~O HO .o 
HO 
0 OH HO~l, HO HO~ H~--~ 
0 OH H~T, 
HO~ 0 
A--7-1_ /~OH 
O O~OH ~p~ ~SH 
- I 0 
0 
15 13. A vaccine comprising a compound of formula (I) according to claim 1 wherein X is a 
carrier protein or an antigen. 
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